Big Law

Eli Lilly Will Sell Low Blood Sugar Drug to Amphastar in Deal Worth $1 Billion

Amphastar Pharmaceuticals will buy Baqsimi from Eli Lilly and Co in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday.

Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal.

Eli Lilly is also eligible to receive milestone payments of up to $450 million based on sales of Baqsimi, the only nasally administered drug to treat severely low blood sugar, or hypoglycemia, in people with diabetes.

Read the source article at finance.yahoo.com

Back to top button